Skip to main content
EJNMMI Research

Table 3 An overview of mean time (days = d) to reach a tumour volume of 2000 mm3 after 213Bi-DOTATATE therapy

From: Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

 

H69 small

H69 large

CA20948 small

CA20948 large

Control

73 ± 19 d

38 ± 11 d

43 ± 20 d

27 ± 14 d

Therapy

102 ± 19 d

110 ± 19 d

76 ± 15 d

77 ± 25 d

Tumour dose (Gy)

5 ± 1 Gy

2.0 ± 0.6 Gy

17 ± 1 Gy

10 ± 5 Gy

Growth delay (control vs therapy)

28 ± 9 d***

73 ± 24 d*

33 ± 17 d NS

50 ± 13 d**

  1. NS not significant
  2. * = P value ≤0.05; ** = P value ≤0.01; *** = P value ≤0.001
  3. The tumour dose (Gy) ± SD was estimated based on the tumour size at T = 0 of therapy and the injected activity (MBq). Growth delay (days) was the ΔT for tumour to reach 2000 mm3 of therapy group vs control group
Back to article page